Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7700255 | 0.85 | CA3 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1679838 | 0.81 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL441642 | 0.79 | TAAR1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16952272 | 0.77 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1561523 | 0.77 | CA3 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4481161 | 0.77 | RIPK1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17552679 | 0.77 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Hydrochloric Acid SCHEMBL2212433 | 0.77 | KMT2A (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29471352 | 0.77 | CA3 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27830893 | 0.77 | DPP4 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589960-A4 | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-BETA INHIBITORS | SCIOS INC (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1575506-A4 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-BETA INHIBITORS | SCIOS INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1572208-A4 | METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE BETA-ADRENERGIC PATHWAY | SCIOS INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1511738-A4 | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-BETA INHIBITORS | SCIOS INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1708712-A1 | TREATMENT OF MALIGNANT GLIOMAS WITH TGF-BETA INHIBITORS | Scios, Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1107959-B1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050245508-A1 | Treatment of malignant gliomas with TGF-beta inhibitors | SCIOS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| EP-1589960-A1 | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-BETA INHIBITORS | Scios, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20040038856-A1 | Treatment of fibroproliferative disorders using TGF-beta inhibitors | SCIOS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004010929-A2 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS | SCIOS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003097615-A1 | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS | SCIOS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2003-04-10 | — | — | US | disclosed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020161010-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2002-10-31 | — | — | US | disclosed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-1107959-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2000012497-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161010-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | PSEN1 3631/4885PSEN2 3361/4885APH1B 2584/4885 |
| US-20050245508-A1 | Treatment of malignant gliomas with TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | PSEN1 1538/4885PSEN2 2640/4885APH1B 2375/4885 |
| US-20040038856-A1 | Treatment of fibroproliferative disorders using TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | PSEN1 3703/4885PSEN2 4345/4885APH1B 3079/4885 |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | PSEN1 3631/4885PSEN2 3361/4885APH1B 2584/4885 |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | PSEN1 4091/4885PSEN2 2641/4885APH1B 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.